Bernard Lim

Acuity Insights, Inc. provides educational services. The company was founded by Rich Emrich, Kelly Dore, and Harold Reiter in September 2014 and is headquartered in Toronto, Canada.

The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class.

Congruix Investment Management, formerly known as Legg Mason International Equities (Singapore), is the investment management division within Legg Mason International Equities (Singapore) Pte Ltd. which is a wholly-owned subsidiary of the Baltimore-based financial services holding company Legg Mason, Inc. (NYSE: LM). Congruix originated as Legg Mason Asset Management Asia and has been managing collective investment schemes in Singapore since 1995. Through a series of joint ventures and acquisitions, the firm has integrated Singaporean investment arms of Western Asset, Batterymarch and Rothschild Asset Management. Congruix manages and sub-advises Asia Pacific equities and mandates on behalf of institutions and retail investors, either as separate accounts or through unit trusts. Their fellow division Legg Mason Investments distributes Legg Mason's Singapore-domiciled unit trusts and Legg Mason's Luxembourg- and Dublin-domiciled mutual fund ranges.

Congruix Investment Management, formerly known as Legg Mason International Equities (Singapore), is the investment management division within Legg Mason International Equities (Singapore) Pte Ltd. which is a wholly-owned subsidiary of the Baltimore-based financial services holding company Legg Mason, Inc. (NYSE: LM). Congruix originated as Legg Mason Asset Management Asia and has been managing collective investment schemes in Singapore since 1995. Through a series of joint ventures and acquisitions, the firm has integrated Singaporean investment arms of Western Asset, Batterymarch and Rothschild Asset Management. Congruix manages and sub-advises Asia Pacific equities and mandates on behalf of institutions and retail investors, either as separate accounts or through unit trusts. Their fellow division Legg Mason Investments distributes Legg Mason's Singapore-domiciled unit trusts and Legg Mason's Luxembourg- and Dublin-domiciled mutual fund ranges.

Threadneedle Investments Singapore (Pte) Ltd. is an investment management firm headquartered in Singapore. They are a subsidiary of Threadneedle Asset Management Holdings Ltd., ultimately owned by Ameriprise Financial, Inc. (NYSE: AMP) in the US. The firm provides a broad range of actively managed investment strategies and solutions for individual, institutional and corporate clients in Asia.

The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class.

Congruix Investment Management, formerly known as Legg Mason International Equities (Singapore), is the investment management division within Legg Mason International Equities (Singapore) Pte Ltd. which is a wholly-owned subsidiary of the Baltimore-based financial services holding company Legg Mason, Inc. (NYSE: LM). Congruix originated as Legg Mason Asset Management Asia and has been managing collective investment schemes in Singapore since 1995. Through a series of joint ventures and acquisitions, the firm has integrated Singaporean investment arms of Western Asset, Batterymarch and Rothschild Asset Management. Congruix manages and sub-advises Asia Pacific equities and mandates on behalf of institutions and retail investors, either as separate accounts or through unit trusts. Their fellow division Legg Mason Investments distributes Legg Mason's Singapore-domiciled unit trusts and Legg Mason's Luxembourg- and Dublin-domiciled mutual fund ranges.

Threadneedle Investments Singapore (Pte) Ltd. is an investment management firm headquartered in Singapore. They are a subsidiary of Threadneedle Asset Management Holdings Ltd., ultimately owned by Ameriprise Financial, Inc. (NYSE: AMP) in the US. The firm provides a broad range of actively managed investment strategies and solutions for individual, institutional and corporate clients in Asia.

The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class.

The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class.

Threadneedle Investments Singapore (Pte) Ltd. is an investment management firm headquartered in Singapore. They are a subsidiary of Threadneedle Asset Management Holdings Ltd., ultimately owned by Ameriprise Financial, Inc. (NYSE: AMP) in the US. The firm provides a broad range of actively managed investment strategies and solutions for individual, institutional and corporate clients in Asia.

The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class.

The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class.

Congruix Investment Management, formerly known as Legg Mason International Equities (Singapore), is the investment management division within Legg Mason International Equities (Singapore) Pte Ltd. which is a wholly-owned subsidiary of the Baltimore-based financial services holding company Legg Mason, Inc. (NYSE: LM). Congruix originated as Legg Mason Asset Management Asia and has been managing collective investment schemes in Singapore since 1995. Through a series of joint ventures and acquisitions, the firm has integrated Singaporean investment arms of Western Asset, Batterymarch and Rothschild Asset Management. Congruix manages and sub-advises Asia Pacific equities and mandates on behalf of institutions and retail investors, either as separate accounts or through unit trusts. Their fellow division Legg Mason Investments distributes Legg Mason's Singapore-domiciled unit trusts and Legg Mason's Luxembourg- and Dublin-domiciled mutual fund ranges.

Congruix Investment Management, formerly known as Legg Mason International Equities (Singapore), is the investment management division within Legg Mason International Equities (Singapore) Pte Ltd. which is a wholly-owned subsidiary of the Baltimore-based financial services holding company Legg Mason, Inc. (NYSE: LM). Congruix originated as Legg Mason Asset Management Asia and has been managing collective investment schemes in Singapore since 1995. Through a series of joint ventures and acquisitions, the firm has integrated Singaporean investment arms of Western Asset, Batterymarch and Rothschild Asset Management. Congruix manages and sub-advises Asia Pacific equities and mandates on behalf of institutions and retail investors, either as separate accounts or through unit trusts. Their fellow division Legg Mason Investments distributes Legg Mason's Singapore-domiciled unit trusts and Legg Mason's Luxembourg- and Dublin-domiciled mutual fund ranges.

The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class.

The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class.

The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class.

The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class.

The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class.

Threadneedle Investments Singapore (Pte) Ltd. is an investment management firm headquartered in Singapore. They are a subsidiary of Threadneedle Asset Management Holdings Ltd., ultimately owned by Ameriprise Financial, Inc. (NYSE: AMP) in the US. The firm provides a broad range of actively managed investment strategies and solutions for individual, institutional and corporate clients in Asia.